189 related articles for article (PubMed ID: 20558835)
1. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
da Silva GN; de Castro Marcondes JP; de Camargo EA; da Silva Passos Júnior GA; Sakamoto-Hojo ET; Salvadori DM
Exp Biol Med (Maywood); 2010 Jul; 235(7):814-24. PubMed ID: 20558835
[TBL] [Abstract][Full Text] [Related]
2. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
[TBL] [Abstract][Full Text] [Related]
3. Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.
da Silva GN; de Camargo EA; Salvadori DM
Mol Biol Rep; 2012 Dec; 39(12):10373-82. PubMed ID: 23053941
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
da Silva GN; Filoni LT; Salvadori MC; Salvadori DMF
Pathol Oncol Res; 2018 Apr; 24(2):407-417. PubMed ID: 28577130
[TBL] [Abstract][Full Text] [Related]
5. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
Fechner G; Perabo FG; Schmidt DH; Haase L; Ludwig E; Schueller H; Blatter J; Mller SC; Albers P
Urology; 2003 Feb; 61(2):468-73. PubMed ID: 12597983
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
[TBL] [Abstract][Full Text] [Related]
9. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
10. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Liu Y; Kwiatkowski DJ
Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
[TBL] [Abstract][Full Text] [Related]
11. The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Dyshlovoy SA; Madanchi R; Hauschild J; Otte K; Alsdorf WH; Schumacher U; Kalinin VI; Silchenko AS; Avilov SA; Honecker F; Stonik VA; Bokemeyer C; von Amsberg G
BMC Cancer; 2017 Feb; 17(1):93. PubMed ID: 28143426
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of urinary bladder cancer cell proliferation by silibinin.
Barros TMB; Lima APB; Almeida TC; da Silva GN
Environ Mol Mutagen; 2020 Apr; 61(4):445-455. PubMed ID: 32078183
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
Mani J; Vallo S; Rakel S; Antonietti P; Gessler F; Blaheta R; Bartsch G; Michaelis M; Cinatl J; Haferkamp A; Kögel D
BMC Cancer; 2015 Apr; 15():224. PubMed ID: 25885284
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil).
Savio AL; da Silva GN; de Camargo EA; Salvadori DM
Mutat Res; 2014 Apr; 762():40-6. PubMed ID: 24625788
[TBL] [Abstract][Full Text] [Related]
15. A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.
Kanigel Winner KR; Costello JC
Pac Symp Biocomput; 2017; 22():611-622. PubMed ID: 27897011
[TBL] [Abstract][Full Text] [Related]
16. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
17. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
van der Heijden AG; Verhaegh G; Jansen CF; Schalken JA; Witjes JA
J Urol; 2005 Apr; 173(4):1375-80. PubMed ID: 15758808
[TBL] [Abstract][Full Text] [Related]
18. Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells.
da Silva GN; Evangelista AF; Magalhães DA; Macedo C; Búfalo MC; Sakamoto-Hojo ET; Passos GA; Salvadori DM
Mol Biol Rep; 2011 Aug; 38(6):4159-70. PubMed ID: 21116856
[TBL] [Abstract][Full Text] [Related]
19. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin.
Lee EK; Jinesh G G; Laing NM; Choi W; McConkey DJ; Kamat AM
Cancer Biol Ther; 2013 Sep; 14(9):812-22. PubMed ID: 23792592
[TBL] [Abstract][Full Text] [Related]
20. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
